Por: Fox Business Business April 16, 2023
Check out what's clicking on FoxBusiness.com Merck & Co. is acquiring Prometheus Biosciences in a $10.8 billion deal. All the shares of Prometheus Biosciences will be acquired by a subsidiary of Merck for $200 per share.. promising immune disease treatments. The acquisition is subject to Prometheus Biosciences shareholder approval. Signage outside Merck & Co. headquarters in Kenilworth, New Jersey. (Photographer: Christopher... + full article
Fox Business USA Business April 16, 2023
Check out what's clicking on FoxBusiness.com Merck & Co. is reportedly in talks to acquire Prometheus Biosciences Inc. The talks are said to be in the late stage with a deal possibly announced as soon as Sunday, according to The Wall Street Journal.A deal is not certain and... + más
Merck to acquire Prometheus Biosciences for $10.8B | Fox Business
Merck Tops Quarterly Profit Estimates but Sees Weaker 2023 Revenue on Lagevrio Sales Drop | MarketWatch
Associated Press USA Health February 24, 2023
A European medical committee recommends rejection of Merck’s COVID-19 treatment, Lagevrio, casting fresh doubt on a pill that also stirs concern among U.S. regulators.A European Medicines Agency committee says marketing authorization for the antiviral pill for use in the... + más
Moderna, Merck announce progress in vaccine against skin cancer to significantly boost survival rate | ABC7
MarketWatch USA Business February 02, 2023
The company is expecting revenue to drop in 2023 amid a decline in sales of Lagevrio, its Covid-19 antiviral, and on Thursday set earnings guidance that was well below Wall Street expectations. Still, Merck Chief Financial Officer Caroline Litchfield said that the company’s... + más
Merck, Moderna detail potential skin cancer vaccine progress | WPLG Local 10
Merck, Moderna detail potential skin cancer vaccine progress | ABC News
ABC News USA Business December 14, 2022
Moderna’s stock soared Tuesday after the COVID-19 vaccine maker detailed progress in developing a preventive shot for a deadly form of skin cancer.The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of... + más
Merck, Moderna detail potential skin cancer vaccine progress | Associated Press
WPLG Local 10 USA Health December 13, 2022
Associated Press USA Health December 13, 2022
RTTNews USA Health October 03, 2022
Shares of Prometheus Biosciences Inc. () closed at an all-time high of $59.01 on Friday (Sep.30, 2022), reflecting a gain of over 100% in 3 months.Prometheus is a biotechnology company pioneering a precision medicine approach in developing novel therapeutic and companion... + más
Dodgers Dugout: Will the next Dodgers closer please stand up? | Los Angeles Times
Brayan Bello stumbles to cap promising rookie campaign and Red Sox again steamrolled by Blue Jays | The Boston Globe
About iurex | Privacy Policy | Disclaimer |